Latest News and Press Releases

NOTICE OF ANNUAL GENERAL MEETING AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2015 and Shareholders' Circular; a covering letter from the...

ASTRAZENECA AND DAIICHI SANKYO TO JOINTLY COMMERCIALISE MOVANTIK IN THE US AstraZeneca today announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for MOVANTIK™ (naloxegol) in the US,...

ASTRAZENECA ANNOUNCES POSITIVE PHASE III TOP-LINE RESULTS FOR PT003 FROM THE PINNACLE 1 AND PINNACLE 2 STUDIES IN COPD AstraZeneca today announced positive top-line results from the Phase...

PEGASUS-TIMI 54 STUDY SHOWS THAT LONG-TERM TREATMENT WITH BRILINTA REDUCED THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF HEART ATTACK Data from 21,000 patient study presented at...

FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE COMMISSION AstraZeneca PLC announced today that, on 10 March 2015, it filed its Annual Report on Form 20-F with the US...

ANNUAL FINANCIAL REPORT AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2014 (Annual Report). A copy of the Annual Report will be...

ASTRAZENECA TO PARTICIPATE IN US FDA ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE AstraZeneca today announced it will participate in the US Food and Drug Administration (FDA) Endocrinologic...

AstraZeneca COMPLETES acquiSITION OF rights to actavis' Branded respiratory portfolio in THE US AND CANADA Acquisition strengthens AstraZeneca's aclidinium respiratory franchise and adds immediate...

17 February 2015 AstraZeneca today announced that Dr Cornelia (Cori) Bargmann will be proposed to shareholders for election as a Non-Executive Director at the Company's Annual General Meeting (AGM)...

AstraZeneca has announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 ("the '834 patent"), protecting PULMICORT RESPULES in the US, is...